FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital ...
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has ...
This suggests that patients who start GLP-1 therapy are also motivated to start and adhere to their sleep apnea treatment ... of Elli Lilly’s Zepbound (tirzepatide) for the treatment of moderate ...
Business Insider on MSN6d
The FDA is about to make weight-loss drugs a lot harder to getfrom sleep apnea to heavy drinking. The drugs became so popular so fast that manufacturers began running out, and patients ...
MarketBeat on MSN19h
What Does the Future Hold for Eli Lilly?GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Hosted on MSN6d
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares RiseThe stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback